All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Poster Presentation Dates

All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.

#	Type	Title	Authors	Category	Keywords
161	Poster Presentation	Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy	Kathrin Davari, PHD; Tristan Holland; Laura Prassmayer; Giulia Longinotti; Kenneth Ganley; Lisa J. Pechilis; Iulia Diaconu; Prashant R. Nambiar; Mike S. Magee; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Christian Ellinger, Dr. Rer. Nat.;	Cellular Therapies	Adoptive immunotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens
303	Oral Presentation	Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable Melanoma (Neo-C-Nivo): Final Results.	Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Richelle DeBlasio, B.Sc.; Joe-Marc JM. Chauvin, PhD; Quanquan Ding; Ornella Pagliano; Amy Rose, RN; John M. Kirkwood, MD; Hassane M. Zarour, MD;	Completed Clinical Trials	Checkpoint blockade; Clinical trial; Immune contexture; TLR
304	Poster Presentation	Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma	Mohammed M. Milhem, MBBS; Yousef Zakharia, MD; Diwakar Davar, MD; Elizabeth I. Buchbinder, MD; Theresa Medina, MD; Adil Daud, MD; Antoni Ribas, MD, PhD; Jiaxin Niu, MD, PhD; Geoffrey T. Gibney, MD; Kim A. Margolin, MD; Anthony J. Olszanski, MD, RPh; Inderjit Mehmi, MD; Takami Sato, MD; Montaser Shaheen, MD; Aaron J. Morris, PhD; David Mauro, MD, PhD; Katie Campbell, PhD; Heather Kelley, MA; Riyue Bao, PhD; George J. Weiner, MD; Jason J. Luke, MD; Arthur M. Krieg, MD; James E. Wooldridge, MD; John M. Kirkwood, MD;	Completed Clinical Trials	Checkpoint blockade; Clinical study; Dendritic cell; T cell; TLR; Tumor microenvironment
393	Poster Presentation	First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results	Claire F. Friedman, MD; Paolo A. Ascierto, MD; Diwakar Davar, MD; Mark O'Hara, MD; Ronnie Shapira-Frommer, MD; Matthew Dallos, MD; Vivek Khemka, MD, MBA; Lee James, MD, PhD; Bruce S. Fischer, MD; Shilpa Demes, PhD; Li Li, PhD; Martin Kozicki, MBC; Palanikumar Ravindran, PhD; Ke Xu, PhD; Georgia Kollia, PhD; Jacqueline Shoukry, MBS; Mona Yunan, BA; Ashish Massey, MD, PhD; Martin Gutierrez, MD;	In-Progress Clinical Trials	Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors
394	Poster Presentation	Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results	Diwakar Davar, MD; Matteo Simonelli, MD; Martin Gutierrez, MD; Emiliano Calvo, MD PhD; Jason Melear, MD; Sarina A. Piha-Paul, MD; Donald Richards, MD, PhD; Matthew Dallos, MD; Janaki Parameswaran, MD; Vinit Kumar, PhD; Xiaochen Zhao, PhD; Santanu Dutta, PhD; Ignacio J. Melero, MD, PhD;	In-Progress Clinical Trials	Antibody; Biomarkers; Checkpoint blockade; Chemokine; Clinical trial; Cytokine; MDSC; Myeloid cells; Solid tumors; Tumor microenvironment
435	Poster Presentation	A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma	Saba S. Shaikh, MD; Yan Zang, MS; Hong Wang, PhD; Xi Yang, BS; Cindy Sander; Amy Rose; Diwakar Davar, MD; Jason J. Luke, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Greg M. Delgoffe, PhD; Yana G. Najjar, MD;	In-Progress Clinical Trials	Angiogenesis; Checkpoint blockade; Clinical trial; Metabolism; Solid tumors; Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment